A Prognostic Merit of Statins in Patients with Chronic Hemodialysis after Percutaneous Coronary Intervention-A 10-Year Follow-Up Study

• Published in: Journal of clinical medicine 2022-01, Vol.11 (2), p.390
• Main Authors: Funamizu, Takehiro, Iwata, Hiroshi, Chikata, Yuichi, Doi, Shinichiro, Endo, Hirohisa, Wada, Hideki, Naito, Ryo, Ogita, Manabu, Kato, Yoshiteru, Okai, Iwao, Dohi, Tomotaka, Kasai, Takatoshi, Isoda, Kikuo, Okazaki, Shinya, Miyauchi, Katsumi, Minamino, Tohru
• Format: Article
• Language: English
• Subjects: Angioplasty; Beta blockers; Cardiovascular disease; Clinical trials; Coronary vessels; Diabetes; Heart attacks; Hemodialysis; Hospitals; Medical prognosis; Mortality; Peritoneal dialysis; Questionnaires; Statins
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11020390

Patients with end-stage renal disease (ESRD) on chronic hemodialysis who are complicated by coronary artery disease (CAD) are at very high risk of cardiovascular (CV) events and mortality. However, the prognostic benefit of statins, which is firmly established in the general population, is still under debate in this particular population. As a part of a prospective single-center percutaneous coronary intervention (PCI) registry database, this study included consecutive patients on chronic hemodialysis who underwent PCI for the first time between 2000 and 2016 ( = 201). Participants were divided into 2 groups by following 2 factors, such as (1) with or without statin, and (2) with or without high LDL-C (> and ≤LDL-C = 93 mg/dL, median) at the time of PCI. The primary endpoint was defined as CV death, and the secondary endpoints included all-cause and non-CV death, and 3 point major cardiovascular adverse events (3P-MACE) which is the composite of CV death, non-fatal myocardial infarction and stroke. The median and range of the follow-up period were 2.8, 0-15.2 years, respectively. Kaplan-Meier analyses showed significantly lower cumulative incidences of primary and secondary endpoints other than non-CV deaths in patients receiving statins. Conversely, no difference was observed when patients were divided by the median LDL-C at the time of PCI ( = 0.11). Multivariate Cox proportional hazard analysis identified statins as an independent predictor of reduced risk of CV death (Hazard ratio of statin use: 0.43, 95% confidence interval 0.18-0.88, = 0.02), all-cause death (HR: 0.50, 95%CI 0.29-0.84, = 0.007) and 3P-MACE (HR: 0.50, 95%CI 0.25-0.93, = 0.03). Statins were associated with reduced risk of adverse outcomes in patients with ESRD following PCI.